Cosmetic cross-reference Noindex: medium evidence

Caraway extract

CAS 85940-31-4

Caraway extract (CAS 85940-31-4) is a pharmaceutical compound with 0 bioactivity targets and 1 adverse event association.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
1
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EPA DSSTox

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Caraway extract
CAS Number
85940-31-4
Source Match
EPA DSSTox
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE DSSTox identifiers DTXSID901018809

Cross-Reference to Chemicals

Same-CAS substance identity is available in the industrial chemicals vertical.

Caraway extract is linked to DTXSID901018809 in DSSTox identifiers.

View industrial chemical data →
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Caraway extract used for in pharmaceutical contexts?

Caraway extract (CAS 85940-31-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Caraway extract?

Caraway extract has 1 DrugCentral/FAERS adverse event association. Rendered reaction terms include Influenza like illness. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Caraway extract also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Carum Carvi Seed Extract with EU status "permitted".

What clinical phase is Caraway extract in?

No phase 1-4 clinical development badge is rendered for Caraway extract because the matched compound identifier rows do not contain a max-phase value.